Related references
Note: Only part of the references are listed.Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma
Ying C. Ou et al.
LEUKEMIA & LYMPHOMA (2021)
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances
Tingyu Wen et al.
LEUKEMIA (2021)
Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review
R. Ghasoub et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2020)
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
John C. Byrd et al.
BLOOD (2020)
Acalabrutinib plus Obinutuzumab in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
Jennifer A. Woyach et al.
CANCER DISCOVERY (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib
Kathrine Aarup et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase
Ling Xiao et al.
CIRCULATION (2020)
Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions
Jennifer Series et al.
HAEMATOLOGICA (2019)
Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma
C. Owen et al.
CURRENT ONCOLOGY (2019)
HYPERTENSION (HTN) IN PATIENTS (PTS) TREATED WITH IBRUTINIB (IBR) FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
M. Sarraf Yazdy et al.
HEMATOLOGICAL ONCOLOGY (2019)
IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT-NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE-BLIND RANDOMIZED CLL12 TRIAL
P. Langerbeins et al.
HEMATOLOGICAL ONCOLOGY (2019)
ZANUBRUTINIB FOR PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
W. Xu et al.
HEMATOLOGICAL ONCOLOGY (2019)
ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
Y. Song et al.
HEMATOLOGICAL ONCOLOGY (2019)
Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece
Maria Dimou et al.
LEUKEMIA & LYMPHOMA (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study
Paolo Ghia et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study
John C. Byrd et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Kerry A. Rogers et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II 'proof-of-concept' iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network
C. Soussain et al.
EUROPEAN JOURNAL OF CANCER (2019)
Cardiovascular Toxicities Associated With Ibrutinib
Joe-Elie Salem et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Farrukh T. Awan et al.
BLOOD ADVANCES (2019)
Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
J. R. Brown et al.
LEUKEMIA (2018)
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer
Tilly Varughese et al.
CLINICAL INFECTIOUS DISEASES (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study
Ajay K. Gopal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma
Alessandro Broccoli et al.
Oncotarget (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study
Xiaojun Huang et al.
CANCER MEDICINE (2018)
Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial
Anthony R. Mato et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
PORTUGUESE REAL-LIFE EXPERIENCE WITH IBRUTINIB OUTSIDE CLINICAL TRIALS - A MULTICENTER ANALYSIS
S. Silva et al.
HEMATOLOGICAL ONCOLOGY (2017)
HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB-3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY
J.F. Seymour et al.
HEMATOLOGICAL ONCOLOGY (2017)
LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP
M. Montillo et al.
HEMATOLOGICAL ONCOLOGY (2017)
Safety and efficacy of single-agent ibrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): A multicenter, open-label, phase 2 study
G.P. Collins et al.
HEMATOLOGICAL ONCOLOGY (2017)
Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)
Elzbieta Iskierka-Jazdzewska et al.
LEUKEMIA & LYMPHOMA (2017)
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib
Tracy E. Wiczer et al.
BLOOD ADVANCES (2017)
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group
Anne-Sophie Michallet et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis
Darryl P. Leong et al.
BLOOD (2016)
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Maria Winqvist et al.
HAEMATOLOGICA (2016)
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Maria Winqvist et al.
HAEMATOLOGICA (2016)
A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma
Natalie Wallace et al.
CLINICAL CASE REPORTS (2016)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling
Julie R. McMullen et al.
BLOOD (2014)
Interaction of the endocrine system with inflammation: a function of energy and volume regulation
Rainer H. Straub
ARTHRITIS RESEARCH & THERAPY (2014)
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib
Amin Aalipour et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
An Observational Study of the Occurrence of Atrial Fibrillation and Hypertension in Patients Treated with Ibrutinib
George Binsah et al.
BLOOD (2014)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The renin-angiotensin-aldosterone system and glucose homeostasis
James Matthew Luther et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2011)
Share Paper
